Dermatología en Costa Rica

Tuesday, January 31, 2023

Topical lidocaine-prilocaine vs. ice packs for laser hair removal


A study published in JAAD compared the effectiveness of ice packs to topical lidocaine-prilocaine for pain reduction during axillary laser hair removal. Participants in this randomized controlled trial received a topical lidocaine-prilocaine mixture to one axilla and ice packs to the other before undergoing hair removal treatment with an 810-nm diode laser monthly for three months. The ice pack was applied to the axilla for 10 minutes before treatment, and the topical anesthetic was applied under occlusion for 60 minutes before the treatment. 

[Read answers to frequently asked questions about the lidocaine shortage.]

Participants reported higher pain scores immediately after treatment with the topical anesthetic compared with ice. After five minutes, pain scores were higher with ice. While topical anesthetics provide longer-lasting anesthesia, the authors indicate that ice packs require less time and help avoid potential side effects associated with topical anesthetics.


Sent from my iPhone

Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica

Clinica Victoria en San Pedro: 4000-1054
Momentum Escazu: 2101-9574

Please excuse the shortness of this message, as it has been sent from
a mobile device.

Is topical spironolactone effective for acne?


A systematic review published in The Journal of Dermatology investigated the efficacy and safety of topical spironolactone in the treatment of acne. The use of topical spironolactone 5% showed a reduction in the number of closed comedones and papules at four and eight weeks. Topical spironolactone 2% was also effective in reducing the number of papules, pustules, and comedones, with efficacy similar to that of clindamycin 1.5% solution. The authors observed that the 2% formulation given for 12 weeks yielded more favorable outcomes compared to 5% spironolactone for six to eight weeks, which, according to the authors, may be due to a longer treatment duration. Despite having a greater drug concentration in the gel formulation (5%), 2% topical spironolactone in solution form displayed more promising results.

[Read about potassium monitoring in women on spironolactone in DermWorld Weekly.]

There were no significant side effects with topical spironolactone. The authors concluded that topical spironolactone is an effective treatment for acne, although more trials are needed with a standardized dose and larger sample size to determine its role in treatment.

Is spironolactone use associated with risk of cancer? Read more in DermWorld Weekly.


Sent from my iPhone

Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica

Clinica Victoria en San Pedro: 4000-1054
Momentum Escazu: 2101-9574

Please excuse the shortness of this message, as it has been sent from
a mobile device.

Clinical, Histopathologic, Immunohistochemical, and Electron Microscopic Findings in Patients With Cutaneous Monkeypox

TAKE-HOME MESSAGE


Abstract 


BACKGROUND

The worldwide outbreak of monkeypox has evidenced the usefulness of the dermatologic manifestations for its diagnosis.

OBJECTIVE

To describe the histopathologic and immunohistochemical findings of monkeypox cutaneous lesions.

METHODS

This is a retrospective histopathologic and immunohistochemical study of 20 patients with positive Monkeypox virus DNA polymerase chain reaction (PCR) and immunohistochemical positivity for Vaccinia virus in cutaneous lesions. Four cases were also examined by electron microscopy.

RESULTS

The most characteristic histopathologic findings consisted of full-thickness epidermal necrosis with hyperplasia and keratinocytic ballooning at the edges. In some cases, the outer root sheath of the hair follicle and the sebaceous gland epithelium were affected. Intraepithelial cytoplasmic inclusion bodies and scattered multinucleated keratinocytes were occasionally found. Immunohistochemically, strong positivity with anti-Vaccinia virus antibody was seen in the cytoplasm of ballooned keratinocytes. Electron microscopy study demonstrated numerous viral particles of monkeypox in affected keratinocytes.

LIMITATIONS

Small sample size. Electron microscopic study was only performed in four cases.

CONCLUSION

Epidermal necrosis and keratinocytic ballooning are the most constant histopathologic findings. Immunohistochemical positivity for Vaccinia virus was mostly detected in the cytoplasm of the ballooned keratinocytes. These findings support the usefulness of histopathologic and immunohistochemical studies of cutaneous lesions for diagnosis of monkeypox.


Journal of the American Academy of Dermatology
Clinical, histopathologic, immunohistochemical and electron microscopic findings in cutaneous monkeypox: A multicenter retrospective case series in Spain
J Am Acad Dermatol 2022 Dec 26;[EPub Ahead of Print], FJ Rodríguez-Cuadrado, L Nájera, D Suárez, G Silvestre, D García-Fresnadillo, G Roustan, L Sánchez-Vázquez, M Jo, C Santonja, MC Garrido-Ruiz, AM Vicente-Montaña, JL Rodríguez-Peralto, L Requena 


Sent from my iPhone

Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica

Clinica Victoria en San Pedro: 4000-1054
Momentum Escazu: 2101-9574

Please excuse the shortness of this message, as it has been sent from
a mobile device.

Wednesday, January 25, 2023

Air Pollution Tied to Psoriasis Occurrence Females, children more sensitive to changes in air pollutants

MONDAY, Jan. 23, 2023 (HealthDay News) -- Short-term air pollutant exposures are associated with psoriasis, according to a study published online Dec. 22 in Frontiers in Public Health.

Ting Wang, from the School of Public Health at Anhui Medical University in Hefei, China, and colleagues examined the short-term effects of air pollutants on outpatients with psoriasis in China between 2015 and 2019. Patients of different ages and genders were included in the stratified analyses.

The researchers found that an increase of 10 μg/m3 of nitrogen dioxide was associated with a 2.1 percent increase in outpatients with psoriasis, while a decrease of 10 μg/m3 of ozone was associated with a 0.8 percent increase in outpatients with psoriasis. Male patients were more sensitive to a change in meteorological factors, while female patients and outpatients with psoriasis aged 17 years or younger were more sensitive to a change in air pollutants.

"In conclusion, short-term air pollutant exposures were correlated with the occurrence of psoriasis in outpatients. Females, and outpatients with psoriasis aged 0 to 17 years old, were more sensitive to the changes in air pollutants," the authors write. "This finding suggests that patients and people at high risk of psoriasis should reduce their time outdoors and improve the quality of their protective gear when the air quality is poor."



Sent from my iPhone

Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica

Clinica Victoria en San Pedro: 4000-1054
Momentum Escazu: 2101-9574

Please excuse the shortness of this message, as it has been sent from
a mobile device.

Saturday, January 21, 2023

Associations Between Diode Laser (810 nm) Therapy and Chronic Wound Healing and Pain Relief Wound Repair and Regeneration

TAKE-HOME MESSAGE

Abstract 

Chronic wounds have become one of the major issues in medicine today, the treatments for which include dressing changes, negative pressure wound therapy, hyperbaric oxygen, light irradiation, surgery and so forth. Nevertheless, the application of diode lasers in chronic wounds has rarely been reported. This retrospective cohort study aimed to evaluate the therapeutic effect of diode laser (810 nm) irradiation on chronic wounds. Eighty-nine patients were enrolled in the study. The control group (41 patients) received traditional dressing change therapy, while the diode laser treatment group (48 patients) were patients received additional treatment with diode laser (810 nm) irradiation for 10 min at each dressing change. Wound healing time was compared between two groups, while the pain relief index was creatively introduced to evaluate the effect of relieving wound pain, which was calculated by the difference in pain scores between the first and last dressing changes divided by the number of treatment days. The wound healing time of the diode laser treatment group was 22.71 ± 8.99 days, which was significantly shorter than that of the control group (37.44 ± 23.42 days). The pain relief index of the diode laser treatment group was 0.081 ± 0.055, which was significantly increased compared with that of the control group (0.057 ± 0.033). Our findings suggest that diode laser irradiation has the potential to promote healing in chronic wounds and relieve wound pain.

Wound Repair and Regeneration
The associations between diode laser (810 nm) therapy and chronic wound healing and pain relief: Light into the chronic wound patient's life
Wound Repair Regen 2022 Dec 21;[EPub Ahead of Print], D Tang, C Liu, X Chen, X Lv, L Yuan, D Xue, H Song 


Sent from my iPhone

Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica

Clinica Victoria en San Pedro: 4000-1054
Momentum Escazu: 2101-9574

Please excuse the shortness of this message, as it has been sent from
a mobile device.

Topical Cannabidiol in the Treatment of Digital Ulcers in Patients With Scleroderma Advances in Skin & Wound Care

TAKE-HOME MESSAGE


Abstract 


OBJECTIVE

To explore the effect of topical cannabidiol (CBD) in treating digital ulcers in patients with systemic sclerosis (SSc).

METHODS

In total, 45 patients with SSc who had digital ulcers were consecutively enrolled between January 2019 and December 2019. Of the participants, 25 were treated with CBD during surgical debridement and 20 were treated with standard local therapy. A numeric rating scale for pain and Health Assessment Questionnaire Disability Index were administered at the baseline and at the end of treatment.

RESULTS

Local treatment with CBD was significantly associated with lower pain scores, higher health assessment scores, and an increase in participants' total hours of sleep. Patients in the control group more frequently required additional analgesic therapy.

CONCLUSIONS

Topical CBD may be a valuable tool to treat pain related to digital ulcers in patients with SSc.


Advances in Skin & Wound Care
Topical Cannabidiol in the Treatment of Digital Ulcers in Patients with Scleroderma: Comparative Analysis and Literature Review
Adv Skin Wound Care 2023 Jan 01;36(1)18-23, A Spinella, M de Pinto, C Baraldi, C Galluzzo, S Testoni, F Lumetti, L Parenti, S Guerzoni, C Salvarani, D Giuggioli 


Sent from my iPhone

Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica

Clinica Victoria en San Pedro: 4000-1054
Momentum Escazu: 2101-9574

Please excuse the shortness of this message, as it has been sent from
a mobile device.

New Razor Technology Improves Appearance and Quality of Life in Men With Pseudofolliculitis Barbae Cutaneous Medicine for the Practitioner

TAKE-HOME MESSAGE

Abstract

Pseudofolliculitis barbae (PFB) consists of ingrown hairs leading to papules, pustules, and discomfort. This prospective, 12-week clinical study aimed to assess the appearance of males with razor bumps and shaving irritation when using a new razor technology with 2 blades separated by a bridge feature (SkinGuard [Procter & Gamble]). The impact on participants' shave-related itching, burning, and stinging severity, as well as quality of life (QOL), also was assessed. In men with PFB, shaving with the test razor at least 5 times per week over a 12-week period improved the appearance and QOL of males with razor bumps and shaving irritation compared with baseline.

Cutaneous Medicine for the Practitioner
New Razor Technology Improves Appearance and Quality of Life in Men With Pseudofolliculitis Barbae
Cutis 2022 Dec 01;110(6)329-334, E Moran, A McMichael, B De Souza, et al 


Sent from my iPhone

Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica

Clinica Victoria en San Pedro: 4000-1054
Momentum Escazu: 2101-9574

Please excuse the shortness of this message, as it has been sent from
a mobile device.

More Evidence Flavanols in Tea, Fruit, and Veg Preserve Memory, Cognition


Consumption of flavonols may preserve memory and cognition over time, new research suggests. Three specific components of flavonols in particular — kaempferol, myricetin, and quercetin — were associated with slower global cognitive decline.

Wednesday, January 18, 2023

Are Your Patients Using This Anti-COVID Secret Weapon?

Cite this: Are Your Patients Using This Anti-COVID Secret Weapon? - Medscape - Jan 10, 2023.

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center.

If your patients vowed to start exercising this year, here's another incentive to help them stick to their guns: They could protect themselves from potentially devastating COVID-19 outcomes like hospitalization and even death.

The evidence is piling up that physical activity can lower the risk of getting very sick from COVID. The CDC, based on a systematic review of the evidence, has reported that "physical activity is associated with a decrease in COVID-19 hospitalizations and deaths, while inactivity increases that risk." Other research has linked regular physical activity with a lower risk of infection, hospitalization, and death from COVID.

The latest such study, from Kaiser Permanente, suggests that exercise in almost any amount can cut the risk of severe or fatal COVID even among high-risk patients like those with hypertension or cardiovascular disease.

"We found that every level of physical activity provided some level of protection," says lead study author Deborah Rohm Young, PhD, director of the Division of Behavioral Research for Kaiser's Southern California Department of Research and Evaluation. "Even a 10-minute walk [per] week is associated with better COVID-19 outcomes."

The best outcomes were seen among "those who are consistently meeting our national guidelines of greater than 150 minutes a week of at least brisk walking," she says. That's 30 minutes of exercise 5 days a week. However, "every bit is beneficial."

Yet, 1 in 4 adults don't get any physical activity outside of their jobs, according to the CDC. That matters as we move into January and COVID numbers trend up. As of press time, the CDC is reporting more than 470,000 weekly cases, compared to about 265,000 for the week ending Oct. 12. On average, over 6,000 people were admitted to the hospital per day from Dec. 31 to Jan. 6, and deaths totaled 2,731 weekly as of Jan. 4.

"The missing aspect in our response to the public health challenge of COVID has been the heightened need for personal and community well-health," says Gene Olinger, PhD, chief science advisor for research company MRI Global, and an adjunct associate professor at Boston University School of Medicine. "Proactive medicine – where individuals optimize nutrition, exercise, sleep, and whole-body meditation – is not a priority in the current health ecosystem. It is changing, and this is good news."

Of course, everyone should still get vaccinated, Young cautions, and not rely on exercise and healthy living alone to ward off severe COVID. "The more we can do to protect ourselves from having bad COVID, it should all be done."

The More Activity Prior to Infection, the Better 

In the Kaiser study, the researchers looked at health records for 194,191 Kaiser adult patients who tested positive for COVID-19 between January 2020 and May 2021.

Patients' activity levels were assessed using a self-report system that Kaiser has used since 2009 involving two questions: "On average, how many days per week do you engage in moderate to strenuous exercise (like a brisk walk)?" and, "On average, how many minutes do you engage in exercise at this level?" To be included in the study, participants had to have completed at least three of these assessments in the 2 years before infection.

The more active a patient was, the better their outcomes tended to be, the researchers found. Likewise, less active patients saw worse outcomes.

In the most dramatic gap, those who were consistently inactive (less than 10 minutes of activity per week) before getting COVID-19 were 91% more likely to be hospitalized, and 291% more likely to die from the disease, than active patients.

Like all studies, this one had limitations. Because it took place before vaccinations were easier to get, it could not assess whether physical activity improved outcomes among the vaccinated. It also did not look at exercise's impact on those with repeat COVID-19 infections. Still, the study suggests that inactive folks should boost their activity to help ward off severe COVID-19.

The exercise benefits come as no surprise to physician Kwadwo Kyeremanteng, MD, head of critical care at the Ottawa Hospital, in Canada, and an associate professor at the University of Ottawa.

"As an ICU physician who has been taking care of COVID patients from day one, I saw on a regular basis that people in poor metabolic health had bad outcomes," says Kyeremanteng, who was not involved in the study. "It was clear early on [that] obesity, diabetes, and metabolic disease [were] risk factors for severe COVID and dying from COVID. Basically, the results of the study correlate with what we saw on the front lines."

Fitness Is No Guarantee 

It's important to note that all trends have outliers. Even highly conditioned athletes who exercise often and hard can — and do — become very ill with COVID and can have lingering symptoms like shortness of breath, severe fatigue, and brain fog.

"In younger athletes and those who are optimally fit, there is evidence that COVID can cause myocardial inflammation [heart damage] in one out of 100," says Olinger. "Fortunately, it is almost always reversible."

And while controversial, the concept of over-exercising (aka overtraining syndrome) has been associated with suppressed immune function and more cases of upper respiratory tract infection, he says.

"However, the level of exercise that one can achieve varies widely," Olinger says. "The data is clear that vaccinations for COVID and regular exercise are key to a lifelong resistance to disease and infections."

What About Exercising After You Get COVID? 

Another caution: While the evidence shows that exercise before getting COVID-19 can help improve outcomes, other research has found that returning to exercise too soon aftercontracting the virus can be dangerous, regardless of one's fitness level. In fact, exercise is likely to make long COVID symptoms worse.

After a bout with COVID-19, return to exercise gradually, says Kyeremanteng. Let your symptoms be your guide. A study in the Journal of Science and Medicine in Sport suggests that athletes with no or minimal symptoms should return to their pre-COVID exercise habits in a "graduated fashion" over 7 to 14 days. "Those with pre-existing medical comorbidities should adopt a more cautious approach," the study says.

"Listen to your body," says Olinger. "You are the only one who knows what feels right."


Sent from my iPhone

Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica

Clinica Victoria en San Pedro: 4000-1054
Momentum Escazu: 2101-9574

Please excuse the shortness of this message, as it has been sent from
a mobile device.

Saturday, January 14, 2023

Exploring the clinical features and risk factors for children tinea capitis complicated with allergic diseases

Xin ZhouWentao LiuSulian YangAngela WuPeiran ChenSongchao YinSybren de HoogMeirong LiPeiying Feng
First published: 23 December 2022

Background

Tinea capitis, atopic dermatitis and allergic rhinitis are the most common disorders endured by prepubescent children. Dermatophyte infections have been linked to allergic disorders, such as increased sensitivity to dermatophytes in patients with atopic dermatitis.

Objectives

To explore the correlation between tinea capitisand allergic diseases in children and to analyse their risk factors.

Methods

This study monitored epidemiological changes in childhood tinea capitis and risk factors for whom with allergic disease in a single centre in three consecutive five-year intervals by reviewing clinical data and multivariate logistic data analysis.

Results

Between 2007 and 2022, there were 127 children patients with tinea capitis, the mean age was 4.83 years, and the male-to-female ratio was 1.76:1. Zoophilic Microsporum canisand Trichophyton mentagrophytes were the most prevalent pathogens, and the proportions remained relatively constant every 5 years. There were 34 (26.8%) children with tinea capitis complicated with allergic disease, among them 14 children with atopic dermatitis/eczema, 13 with allergic rhinitis, 8 urticaria, 6 food allergies and 1 allergic asthma. Male, kerion, zoophilic species infections and animal contact history were prevalent features in allergic disease combined with tinea capitis. Patients with tinea capitis plus allergic disease mostly had a family history with similar complications.

Conclusion

M. canis and T. mentagrophytes were the most prevalent pathogens of tinea capitis in the last 15 years; atopic dermatitis/eczema and allergic rhinitis were the most frequently associated allergic diseases. Male, kerion, zoophilic pathogen and animal contact history are risk factors.


Sent from my iPhone

Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica

Clinica Victoria en San Pedro: 4000-1054
Momentum Escazu: 2101-9574

Please excuse the shortness of this message, as it has been sent from
a mobile device.

Correlation of plasma levels of itraconazole with treatment response at 4 weeks in chronic dermatophytosis: Results of a randomised controlled trial

Hitesh BhalaviDipika ShawHitaishi MehtaTarun NarangNaresh SachdevaNusrat ShafiqShivaprakash M. RudramurthySunil Dogra
First published: 01 December 2022

Background

Itraconazole in varying doses and duration is being frequently used for the management of dermatophytosis. There is a scarcity of studies on the bioavailability of various itraconazole brands available in the market.

Aims and Objectives

The aim of this study was to determine the plasma concentration of itraconazole of various brands and its correlation with clinical efficacy in chronic dermatophytosis.

Materials and Methods

One hundred patients with chronic dermatophytosis with age >18 years were studied at the outpatient clinic of our tertiary care hospital. Plasma itraconazole level was estimated on Week 2 and Week 4 after randomly dividing the patients into Groups A, B and C who received cap itraconazole 100 mg twice a day of innovator, multinational and local generic brands, respectively, for 4 weeks. Both efficacy (cure, partial cure or no cure), safety and recurrence were compared between the three groups.

Results

At 4 weeks, number of patients classified as 'cured' were 10/26 (38.4%) in Group A, 5/22 in Group B (22.7%) and 3/21 (14.2%) in Group C (p = .002). Mycological cure rates at Week 4 in Groups A, B and C were 21 (80.8%), 17 (81.0%) and 5 (26.3%), respectively (p = .006). Plasma levels of itraconazole were comparable between the three groups at Week 2 and Week 4. No statistically significant correlation was found between itraconazole levels and treatment response in any of the groups at 4 weeks. Incidence of adverse effects and recurrence rates was also similar among the three groups.

Conclusion

Cure rates for chronic dermatophytosis were poor with all three itraconazole brands at 4 weeks of treatment. Higher cure rates were obtained with innovator drug as compared to multinational and local generic brands at 4 weeks. Plasma levels of the three drugs were however similar, indicating that factors other than serum bioavailability are at play in determining response of chronic dermatophyte infections to oral itraconazole.


Sent from my iPhone

Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica

Clinica Victoria en San Pedro: 4000-1054
Momentum Escazu: 2101-9574

Please excuse the shortness of this message, as it has been sent from
a mobile device.

Thursday, January 12, 2023

Machine Learning Approach May Help Identify Melanoma Survivors Who Face a High Risk of Cancer Recurrence


Researchers have developed and validated a machine learning-based method to predict which patients with early-stage melanoma are most likely to experience a cancer recurrence.

The tool, described in npj Precision Oncology, may help identify patients who would benefit from aggressive treatment even at early stages of melanoma.

Most patients with early-stage melanoma are treated with surgery to remove cancerous cells, but patients with more advanced cancer often receive immune checkpoint inhibitors, which effectively strengthen the immune response against tumor cells but also carry significant side effects.

"There is an urgent need to develop predictive tools to assist in the selection of high-risk patients for whom the benefits of immune checkpoint inhibitors would justify the high rate of morbid and potentially fatal immunologic adverse events observed with this therapeutic class," said senior author Yevgeniy R. Semenov, MD, Massachusetts General Hospital, Boston, Massachusetts. "Reliable prediction of melanoma recurrence can enable more precise treatment selection for immunotherapy, reduce progression to metastatic disease and improve melanoma survival while minimising exposure to treatment toxicities."

To help achieve this, Dr. Semenov and colleagues assessed the effectiveness of algorithms based on machine learning that used data from patient electronic health records to predict melanoma recurrence. Specifically, the team collected data from 1,720 patients with early-stage melanomas (1,172 from MassGen and 548 from Dana-Farber Cancer Institute in Boston) and extracted 36 clinical and pathologic features of these cancers from electronic health records to predict patients' recurrence risk with machine learning algorithms. Models were evaluated internally and externally.

In the internal and external validations, respectively, the model achieved a recurrence classification performance of area under the curve (AUC) 0.845 and 0.812, and a time-to-event prediction performance of time-dependent AUC of 0.853 and 0.820. Breslow tumour thickness and mitotic rate were identified as the most predictive features.

"Our comprehensive risk prediction platform using novel machine learning approaches to determine the risk of early-stage melanoma recurrence reached high levels of classification and time to event prediction accuracy," says Semenov. "Our results suggest that machine learning algorithms can extract predictive signals from clinicopathologic features for early-stage melanoma recurrence prediction, which will enable the identification of patients who may benefit from adjuvant immunotherapy."

Reference:https://www.nature.com/articles/s41698-022-00321-4

SOURCE: Massachusetts General Hospital


Sent from my iPhone

Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica

Clinica Victoria en San Pedro: 4000-1054
Momentum Escazu: 2101-9574

Please excuse the shortness of this message, as it has been sent from
a mobile device.

Immune Checkpoint Inhibitor-Induced Myocarditis Is Associated With Changes in 3 Biomarkers


In a study published in JACC: CardioOncology, investigators found that nearly all patients with cancer who were diagnosed with myocarditis after being treated with immune checkpoint inhibitors (ICIs) had early signs of muscle destruction and liver damage.

"While immune checkpoint inhibitors have revolutionised the treatment of various cancers, patients who develop the rare complication of myocarditis often present late with at least a 50% chance of death," said Salim Hayek, MD, University of Michigan Health Frankel Cardiovascular Center Clinics, Ann Arbor, Michigan. "Diagnosing immune checkpoint inhibitor myocarditis is challenging, given that there is no one test that can differentiate it from other causes of cardiac injury. By the time patients present to the hospital, it is often too late. Diagnosing patients early allows us to start immunosuppressive therapy sooner and give patients a better chance of survival."

The researchers analysed more than 2,600 patients with cancer treated with ICIs at the University of Michigan Health between June 2014 and Dec. 2021. The vast majority of patients diagnosed with ICI-induced myocarditis also had early signs of muscle injury and liver damage, even prior to hospitalisation. Of the patients, 95% had at least 3 elevated biomarkers -- aspartate aminotransferase (AST), alanine aminotransferase (ALT), and creatine phosphokinase (CPK) -- compared with just 5% of patients without myocarditis.

CPK was most strongly linked to the development of ICI-induced myocarditis, as well as all-cause death.

"Abnormalities in these biomarkers should prompt clinicians to test for cardiac injury using high sensitivity troponin," said Dr. Hayek. "Conversely, patients suspected of immune checkpoint myocarditis should have creatine phosphokinase levels measured. If low, or within normal limits, then the diagnosis of immune checkpoint myocarditis is highly unlikely."

"It makes sense that myocarditis related to immune checkpoint inhibitors does not occur in isolation, given a raging immune system is expected to affect several organs and particularly the muscles," said coauthor Joe-Elie Salem, MD, Sorbonne Université, Paris, France. "A large variety of antigens targeted by auto-reactive T-cells boosted by ICIs are shared between the myocardium and the peripheral muscles. Myositis is a central component of complications related to this class of drugs."

Reference:https://www.sciencedirect.com/science/article/pii/S2666087322004598

SOURCE: Michigan Medicine - University of Michigan


Sent from my iPhone

Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica

Clinica Victoria en San Pedro: 4000-1054
Momentum Escazu: 2101-9574

Please excuse the shortness of this message, as it has been sent from
a mobile device.

Saturday, January 07, 2023

Topical Options for Treating Melasma Continue to Expand

In the opinion of Seemal R. Desai, MD, dermatologists are obligated to tell their patients with melasma that their condition is a chronic disease with no cure.

"We have to set expectations upfront, because you all know the history," Desai, founder and medical director of Innovative Dermatology in Dallas, said at the annual meeting of the American Academy of Dermatology. "You get someone better, their melasma gets lighter, and then they're lost to follow-up for a year. Then they're back to your office after that beach vacation because their melasma has come back with a vengeance because they were out in the sun too much. We have to tell our patients that melasma therapy is a journey of skin lightening but it's not going to be a one-stop shop of getting it completely cured."

As for treatment of melasma, "hydroquinone is still our workhorse, our gold standard." Desai said. "I tell patients, 'I'm going to keep you on it for 16 weeks. Then you're going to come back. I'm going to see where you are, and we'll move into the nonhydroquinone therapies once your disease is under control.' "

However, new therapies for melasma are needed because long-term use of hydroquinone can lead to complications such as ochronosis, nail discoloration, conjunctival melanosis, and corneal degeneration.

Emerging Treatments

A growing number of synthetic and natural agents have emerged as off-label, second-line treatments for melasma, including azelaic acid, which inhibits tyrosinase and mitochondrial enzymes. Desai described azelaic acid as his "go to" nonhydroquinone option for skin lightening. In one study, 20% azelaic acid was used twice daily in 155 patients with facial melasma. Of these, 73% showed improvement after 6 months of therapy. Side effects were minimal and included erythema, pruritus, and burning.

Another option is topically compounded methimazole, a potent peroxidase inhibitor that causes morphologic change in melanocytes. "You can get it compounded as a 5% cream," he said of the antithyroid agent. "It's not that expensive, and even high concentrations are not melanocytotoxic. There's minimal systemic absorption because the molecule is large, so there really is not any effect on TSH [thyroid-stimulating hormone] or T4 levels."

Kojic acid dipalmitate, an antibiotic produced by many species of Aspergillus and Penicillium, can also be used as a second-line melasma treatment. Unlike kojic acid, kojic acid dipalmitate is more stable to light, heat, pH, and oxidation, and is also compatible with most organic sunscreens. It works by inhibiting tyrosinase. "It's already available overseas and will soon be available in the U.S. as a derivative of kojic acid," he said.

There is also vitamin C serum, which reduces tyrosinase activity via an antioxidant effect. "When you combine it with azelaic acid or sunscreen, vitamin C helps to augment the response," Desai said. In one study that compared 5% ascorbic acid with 4% hydroquinone, 62.5% vs. 93% of patients improved, respectively, but side effects were more prominent in those who received 4% hydroquinone (68.7% vs. 6.2%).

An additional off-label option for melasma is oral tranexamic acid, which controls pigmentation by inhibiting the release of inflammatory mediators, specifically prostaglandins and arachidonic acid, which are involved in melanogenesis.

Desai often uses a dose of 325 mg twice daily. "Think of tranexamic acid as an anti-inflammatory," he said. Tranexamic acid is contraindicated in patients who are currently taking or have previously taken anticoagulant medications; those who are pregnant or breastfeeding, or are smokers; and in those with renal, cardiac, and/or pulmonary disease. It has a half-life of about 7.5 hours, so the twice daily dosing "is quite effective," he said.

"Do I leave my patients on this for years at a time to see if it's going to work? No. When this works in treating melasma it works very quickly. I tell patients they're going to see results in the first 8-12 weeks. That's the beauty of using this orally."

Another emerging therapy is Rubus occidentalis(black raspberry), a botanical-based ingredient in a 3% topical suspension that was compared with 4% hydroquinone in a randomized placebo-controlled trial. In the study, efficacy of Rubus occidentalis was considered comparable to that of hydroquinone. "This not only blocks melanogenesis, it also helps to block melanosome transfer," said Desai, who is a past president of the Skin of Color Society.

Another natural option for melasma patients is topical cysteamine, which is the simplest aminothiol physiologically produced in human cells from the essential amino acid cysteine. "This is great for patients with recalcitrant disease, or for patients who, after 12-16 weeks of hydroquinone, you want them to have a break. I use it as a 5% concentration, and it works nicely," he said. Cysteamine is also highly concentrated in human milk.

Desai disclosed that he performs clinical trials and consulting for many companies including L'Oréal, Galderma, Allergan, and AbbVie.

This article originally appeared on MDedge.com, part of the Medscape Professional Network.


Sent from my iPhone

Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica

Clinica Victoria en San Pedro: 4000-1054
Momentum Escazu: 2101-9574

Please excuse the shortness of this message, as it has been sent from
a mobile device.